Omada Health (OMDA) Q4 2025: Gross Margin Hits 73% as Multi-Condition Platform Drives Durable Scale

March 5, 2026 | By EarningsIQ Research

Omada Health’s fourth quarter marked a pivotal inflection in both profitability and commercial scale, with expanding gross margins and robust member growth unlocking operating leverage across its cardiometabolic care platform. The company’s focus on multi-condition integration, AI-enabled engagement, and new offerings like GLP-1 FlexCare and cholesterol management is reshaping its long-term economics and competitive positioning. 2026 guidance points to continued double-digit growth, with upside potential from nascent product launches and ongoing enrollment optimization.

Summary

  • Margin Expansion Outpaces Revenue: Gross margin reached a record 73%, reflecting operational leverage and product mix shift.
  • Integrated Platform Accelerates Adoption: Multi-condition growth and AI-driven engagement fuel member and revenue gains.
  • New Program Launches Set Stage for Upside: GLP-1 FlexCare, prescribing, and cholesterol programs offer incremental growth not yet in guidance.

Performance Analysis

Omada Health delivered a breakout quarter, achieving its first GAAP net income and record gross margins, as revenue grew 58% year-over-year in Q4 and 53% for the full year. The company ended 2025 supporting 886,000 members, up 55% from the prior year, with net new additions in Q4 nearly doubling versus last year’s comparable period. Growth was broad-based, spanning weight health, diabetes, hypertension, and GLP-1 programs, each contributing materially to the top line.

Gross profit growth outpaced revenue, with Q4 GAAP gross profit up 67% and adjusted gross margin climbing to 73%, a 320 basis point improvement. This expansion was driven by scale efficiencies, higher-margin multi-condition programs, and AI-enabled care delivery optimization. Operating expenses rose just 24% for the year, supporting a 19-point swing in adjusted EBITDA margin and positive operating cash flow. Notably, Omada converted 40% of incremental revenue to adjusted EBITDA, underscoring the scalability of its model.

  • Leverage from Multi-Condition Sales: Diabetes and hypertension programs, Omada’s highest-priced offerings, grew at or above 45% and boosted gross profit mix.
  • AI-Driven Efficiency: AI tools, such as Omada Spark and context summarization, reduced care team labor and improved engagement, driving margin gains.
  • Commercial Channel Strength: Covered lives rose by 5 million, with PBM channel partnerships leading additions and supporting future enrollment pipeline.

Operating cash flow turned positive and the company exited with $222 million in cash and no debt, providing ample flexibility for continued investment.

Executive Commentary

"We became a public company, delivered 53% revenue growth for the year, and achieved GAAP profitability for the first time in Q4... Omada's technology and operational platform, our clinical programs, our peer-reviewed research, productive distribution channels, and more than a decade of rich and unique data are strongly suited for this exact moment, for when customer demand for chronic care solutions, a rapidly evolving GLP-1 marketplace, and AI-driven innovation converge."

Sean Duffy, Co-founder and Chief Executive Officer

"We converted 40% of incremental revenue to the adjusted EBITDA line in 2025, which continues to highlight the scalability of our business... Our guidance for 2026 does not embed meaningful contributions from GLP-1 prescribing, GLP-1 FlexCare, or our cholesterol program. If we achieve revenue upside, we would expect a portion to contribute to a stronger adjusted EBITDA."

Steve Cook, Chief Financial Officer

Strategic Positioning

1. Multi-Condition Platform as a Differentiator

Omada’s integrated approach—supporting weight health, diabetes, hypertension, cholesterol, musculoskeletal (MSK), and GLP-1 care—positions it as a single partner for employers and health plans seeking to consolidate point solutions. This model is resonating amid buyer fatigue from fragmented offerings, and is supported by evidence-based outcomes and payer relationships that treat Omada as a healthcare provider, not just a digital tool.

2. AI-Enabled Engagement and Efficiency

AI is embedded across member experience and care team operations, with Omada Spark and Meal Map driving higher engagement and improved food tracking, a key predictor of sustained weight management. For care teams, AI tools streamline administrative tasks and enable greater personalization, while engineering productivity is boosted through AI-assisted coding. Omada’s proprietary dataset—billions of data points—fuels ongoing product innovation and defensibility.

3. Commercial Traction and Channel Expansion

Covered lives surpassed 25 million, with PBM partnerships leading new additions and multi-condition adoption gaining momentum. Enrollment yield improved 24% year-over-year through digital and omnichannel marketing optimization, and the company sees continued runway for further conversion gains in 2026. The launch of GLP-1 FlexCare targets the 55% of employers not currently covering GLP-1s, offering a new revenue stream and expanding addressable market.

4. New Program Launches Drive Optionality

GLP-1 prescribing, FlexCare, and the cholesterol program are early-stage but priced above legacy offerings and expected to lift ARPU as adoption scales. The cholesterol program, catalyzed by direct customer demand, launched with a 300,000-employee enterprise and is slated for broader rollout in 2027. Management expects these new programs to accelerate the pace of incremental revenue contribution versus prior launches.

5. Financial Discipline and Operating Leverage

Operating expense growth remains well below revenue, with scale from channel partnerships, unified salesforce, and disciplined R&D investment supporting margin expansion. The company’s commitment to 20%+ adjusted EBITDA margins over time is underpinned by demonstrated ability to convert incremental revenue into profit, even as it invests for growth.

Key Considerations

Omada’s Q4 capped a year of outperformance, with structural advantages and commercial momentum positioning the company for durable growth as chronic care demand intensifies. The company’s guidance methodology builds in conservatism, creating potential for upside as new programs gain traction.

Key Considerations:

  • Platform Stickiness: Multi-condition integration and evidence-driven outcomes support high retention and cross-sell, increasing Omada’s relevance to enterprise buyers.
  • AI as a Force Multiplier: Proprietary data and embedded AI tools are driving both engagement and cost efficiency, creating a defensible moat and supporting scalable economics.
  • Untapped Market Opportunity: Current penetration across eligible lives remains below 10% of a $138 billion addressable market, with significant white space ahead.
  • Conservative Guidance Baseline: 2026 outlook excludes revenue from new programs and assumes no further enrollment improvements, setting a low bar for potential beats.
  • Commercial Channel Leverage: PBM and employer partnerships are accelerating covered lives and funneling new members, supporting future top-line visibility.

Risks

Key risks include potential deceleration in member growth as the base scales, competitive pressure from both digital health and incumbent healthcare providers, and the pace of adoption for new offerings like GLP-1 FlexCare and cholesterol management. Regulatory changes—particularly in virtual care reimbursement—and macroeconomic pressures on employer benefits budgets could impact enrollment rates or pricing power. Management’s guidance depends on stable engagement and retention trends, with upside tied to successful execution on new product launches and continued commercial channel expansion.

Forward Outlook

For Q1 2026, Omada expects revenue to be roughly flat sequentially due to a strong Q4 and a one-time $2 million revenue benefit not recurring, with sequential growth resuming through the year.

  • Full-year 2026 revenue guidance: $312 million to $322 million (22% YoY growth at midpoint)
  • Full-year 2026 adjusted EBITDA: $7 million to $15 million (midpoint up $5 million YoY)

Management emphasized that guidance does not include material contributions from GLP-1 prescribing, FlexCare, or cholesterol programs, nor does it assume further improvement in enrollment conversion rates. Upside is possible as new products gain market traction and conversion initiatives deliver results.

  • Revenue visibility is anchored to existing members and historical engagement, with new product wins representing potential upside levers.
  • Gross margin is expected to remain at or above the 70% long-term target as scale and AI continue to drive efficiency.

Takeaways

Omada Health’s Q4 2025 results validate its multi-condition platform strategy and ability to scale profitably in a rapidly evolving chronic care market.

  • Operating Leverage Unlocks Profitability: Margin expansion and cost discipline enabled Omada to achieve GAAP profitability and positive cash flow, with incremental revenue translating efficiently to EBITDA.
  • Product Innovation Expands TAM: New launches in GLP-1 prescribing, FlexCare, and cholesterol management are positioned to drive incremental revenue and ARPU growth as adoption scales.
  • 2026 Watchpoints: Key areas for investors include the pace of new program adoption, further improvements in enrollment conversion, and Omada’s ability to sustain margin gains while investing for growth.

Conclusion

Omada Health exited 2025 with strong commercial momentum, record margins, and a scalable platform that is increasingly central to employer and health plan strategies. The company’s conservative 2026 guidance leaves room for positive surprises, with new product launches and operational optimization set to drive further upside.

Industry Read-Through

Omada’s results and strategy underscore a decisive shift toward integrated, multi-condition digital health solutions as employers and payers seek to consolidate point solutions and manage rising chronic care costs. The company’s success with AI-driven engagement and clinical outcomes sets a new bar for digital health platforms, highlighting the importance of proprietary data and operational scale. For the broader sector, Omada’s margin trajectory and commercial channel leverage signal that digital health winners will be those who can deliver both clinical and financial ROI across multiple conditions while maintaining disciplined growth and innovation cadence.

OMDA Health Care Digital Health AI Chronic Care Membership GLP-1 Multi-Condition